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Objective: Recent studies have reported different sac behavior after endovascular repair of abdominal aortic aneurysms,
depending on the endografts. This study was designed to evaluate mid-term outcome and sac behavior after treatment
with the Gore Excluder stent-graft.
Methods: Between June 1999 and January 2005, 109 selected patients with suitable anatomy were treated electively for
abdominal aortic aneurysm with the Excluder stent graft. Data were prospectively collected in a computerised database
and included demographics, details of the aortoiliac anatomy, procedural and clinical success, and postoperative
complications. Postoperative sac size and the presence of endoleaks were assessed with computed tomography scans
obtained at 1, 6, and 12 months, and yearly thereafter. All diameter measures in patients followed for >1 year (84.4%)
were analyzed.
Results: Assisted primary technical success was achieved in 108 cases (99.1%). No type I endoleaks and 12 (11.1%) type II
endoleaks were recorded <1 month from the procedure. Mean follow-up was 29.6  16.1 months. We recorded one
new-onset type IA endoleak, complete resolution of five type II endoleaks, and eight new-onset type II endoleaks. The overall
prevalence of type II endoleaks was 14%. Shrinkage at 1, 2, 3, and 4 years was observed in 20.7%, 30.5%, 38.9%, and 36.8% of
cases. The presence of type II endoleak influenced the trend of aneurysm size throughout the 4 years. Aneurysms without
endoleak shrankmore than aneurysmswith type II endoleak (P< .0001).We observed two cases of sac enlargement due to the
presence of endoleaks. No cases of endotension with sac enlargement, late open conversion, or aneurysm-related deaths were
observed. Unchanged aneurysmal sacs remained stable during follow-up, with no adverse events.
Conclusions: Endovascular treatment with the Excluder device in selected patients produces low rates of shrinkage, but
this peculiar sac behavior does not affect mid-term clinical success. ( J Vasc Surg 2005;42:1052–7.)After more than a decade of endovascular abdominal
aortic repair (EVAR), manufactured endografts with a va-
riety of designs, materials, and implantation techniques
have been developed.
Mid-term studies of EVAR demonstrate different sac
behavior with the commercially available endografts.1-4 The
Excluder device (W. L. Gore and Assoc, Flagstaff, Ariz) has
been associated with a lower incidence of shrinkage, even in
the absence of demonstrated endoleaks, at 1 and 2 years.2,3
Despite the lack of shrinkage, the rupture rate for abdominal
aortic aneurysms (AAAs) treated with the Excluder bifurcated
graft has been reported to be very low.5
Cho et al6 recently observed late aneurysm sac growth
after EVAR with the Excluder device, with a probability of
freedom from sac enlargement of only 43% at 4 years. Most
of these enlargements were endoleak-free and could be
explained as endotension due to exudate of fluid through
the graft material or from undetected microleaks.
The objective of this single center study was to evaluate
the mid-term clinical success rate7 after of AAAs with the
Excluder graft and to assess the behavior of the aneurysmal
sac.
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1052MATERIALS AND METHODS
Between June 1999 and January 2005, 1,554 patients
were electively treated at “Vita-Salute” University for
AAAs: 1,410 were treated with open surgery (90.7%) and
144 patients (9.3%) with EVAR. Patients were treated with
EVAR only if they were considered to be unfit for conven-
tional open repair because of comorbidities, such as hostile
abdomen and old age, and presented a favorable anatomy.8
Different commercially available endografts were used, and
the choice of the device was determined by aortic morphol-
ogy and availability of the stent graft. The Excluder stent
graft was used in 109 cases.
There were 97 men (89.0%) and 12 women (11.0%)
with a mean age of 72.3  7.2 years (range, 50.6 to 88.4
years); 104 patients (95.4%) presented with an asymptom-
atic aneurysm, and five patients were symptomatic (4.6%).
Risk factors were classified according to the Society of
Vascular Surgery/International Society of Cardiovascular
Surgery (SVS/ISCVS) risk classification9 (Table). Preoper-
ative anaesthetic risk was measured with American Associ-
ation of Anaesthetists (ASA) score: 22 patients (20.2%)
were graded ASA I and II, 79 (72.5 %) ASA III, and 8
(7.3%) ASA IV.
Patients underwent imaging for morphologic assess-
ment of their AAA, consisting of 3-mm slices spiral com-
puted tomography (CT) scans in 105 (96.3%) or magnetic
resonance angiography in four (3.7%). Preoperative digital
angiography in frontal and oblique planes with a graduated
catheter was performed in 67 patients (60.2%). Preopera-
22 (
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performed in all patients.
The mean maximum aneurysm diameter, measured as
the smaller axis on the largest axial CT cross-sectional
image,10 was 50.7  8.7 mm (range, 41 to 80 mm). The
maximum aneurysm diameter was 55 mm in 69 patients
(63.3 %) and55 mm in 40 patients (36.7%). As far as the
morphology is concerned, the AAAs were classified11 grade
I in 37 patients (33.9%) and grade II in 72 patients (66.1%).
No grade III or IV AAAs were treated.
The mean aortic neck diameter was 22.4  2.7 mm
(range, 17 to 29mm), and themean iliac neck diameter was
11.3  1.2 mm (range, 9 to 16 mm). The mean infrarenal
aortic neck length was 25.1  4.8 mm (range, 16 to 39
mm). In 13 patients (11.9%), the aortic neck length was
20 mm and none was 15 mm. The mean proximal
oversizing was 14.4%  4.5%, and the mean distal oversiz-
ing was 14.7%  3.6%.
All procedures were performed in the operating room
using a portable digital C-arm image intensifier. General
anesthesia was used for 46 procedures (42.2%), epidural or
subarachnoid anaesthesia was used in 55 (50.5%), and local
anaesthesia was used in 8 cases (7.3%).
The access vessel for the main body (18F sheath) was the
common femoral artery in 108 patients (99.1%), and the
access was open in all cases. In one patient, we used the
common iliac artery as the access vessel for themain body.The
main access for the contralateral leg (12F sheath) was the
common femoral artery. The access was open in the presence
of small diameter or diseased vessels in 39 patients (35.8%)
and percutaneous in the others. Themean total operative time
was 7512minutes. Themeanblood losswas 19786mL.
Twelve patients (11.0%) required postoperative blood trans-
fusions. The amount of intravascular contrast agent was 187
 97 mL, and the mean time of fluoroscopy was 21  16
minutes, with a mean dose of 68 Gy/cm2.
Reported results and method used for measuring
changes in the dimension of a sac aneurysm are in accor-
dance to the current reporting standards for EVAR pre-
pared and revised by the Ad Hoc Committee for Standard-
ized Reporting Practices in Vascular Surgery (SVS/
AAVS).7 Patients were evaluated with postprocedure
contrast CT scans, with scheduled follow-up imaging at 1,
6, and 12 months, and yearly thereafter. Angiograms were
Table I. Society of Vascular Surgery/International Societ
0
Category n (%) 
Tobacco 54 (49.5)
Hypertension 32 (29.4) 
Diabetes 92 (84.4)
Hyperlipidemia 47 (43.1) 
Cardiac status 66 (60.6)
Carotid status 83 (76.1)
Renal status 95 (87.2)
Pulmonary status 71 (65.1)obtained in selected cases. The 1-month postoperative CTscan was the reference scan against which all subsequent
measurements were compared.
Results are reported as mean  SD. All measurements
were prospectively performed by one surgeon (E. C.) to
reduce interobserver variability.12 Measurements were per-
formed on a hard copy by using a digital caliper for exams
performed before 2001 and on a workstation by using an
electronic caliper with commercially available software
when it became available at our center in 2001. Three-
dimensional CT with reformatted images perpendicular to
blood flow has helped in avoiding diameter overestimation.
A variation of5 mm in the measurements was considered
significant for either enlargement or shrinkage.
Confidence intervals (95% CI) of the proportions were
calculated by the exact method. The distribution of survival
was determined using the Kaplan-Meier method. All diam-
eter measures in patients followed at 1 year or more (91
cases) were analyzed with the repeated measures analysis of
variance method with PROC MIXED by using SAS statis-
tical software (SAS Institute Inc, Cary, NC) for Windows
(Microsoft, Redmond, Wash). The presence of type II
endoleak or55 mm aneurysm were the main unit factors,
and time was the within-subject factor.
RESULTS
Endovascular stent-graft deployment was successful in
108 patients (99.1%). One patient was converted to open
procedure because it was not possible to advance the sheath
through the iliac axis. No intraoperative death occurred.
Primary technical success was achieved in 108 patients
(99.1%). We recorded three type IA endoleaks (2.8%) and
one type IB endoleak (0.9%). An adjunctive cuff was used in
four cases. Assisted primary technical success was achieved
in 108 cases (99.1%). We recorded two (1.9%) punctured
site pseudoaneurysms that resolved after ultrasound-
guided compression.
A CT scan examination done 1 month from the
procedure demonstrated no type I endoleaks and 12 type II
endoleaks (11.1%). The source of the type II endoleaks was
the inferior mesenteric artery in four cases, a lumbar artery
in three cases, and unidentified in five cases.
Additional endovascular procedures (iliac artery percu-
taneous angioplasty) were necessary in six patients (5.6%)
to improve access or to treat concomitant pathology. Ad-
ardiovascular Surgery risk classification9 (N  109)
1 2 3
(%) n (%) n (%)
33.9) 11 (10.1) 7 (6.4)
35.8) 24 (22.0) 14 (12.8)
11.9) 4 (3.7) 0
45.0) 4 (3.7) 9 (8.3)
26.6) 14 (12.8) 0
19.3) 3 (2.8) 2 (1.8)
11.0) 2 (1.8) 0
20.2) 11 (10.1) 5 (4.6)y of C
n 
37 (
39 (
13 (
49 (
29 (
21 (
12 (ditional surgical procedures (endarterectomy and patch
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artery pathology in 12 patients (11.1%). Balloon thrombec-
tomy was performed in one additional case.
Seventeen patients (15.7%) required temporary recov-
ery in an intensive care unit for severe chronic obstructive
pulmonary or coronary artery disease. No adverse events
specifically related to the stent-graft deployment were ob-
served. The mean postoperative length-of-hospital stay was
3.4  1.9 days.
Two patients were lost to follow-up. Mean follow-up
was 29.6  16.1 months (range, 1.9 to 68.6 months).
Overall survival at 1, 2, 3, and 4 years was 99%, 92%, 89%,
and 78%, respectively (Fig. 1). We recorded 11 late deaths
(10.3%); none was aneurysm-related. No late open conver-
sion occurred. One case of groin infection was managed
conservatively.
Assisted endovascular clinical success was achieved in all
followed patients.One case of new-onset type I endoleakwith
a 6-mm sac enlargement observed 11months after the proce-
dure was successfully managed with an adjunctive proximal
cuff. After 3 years, this patient had complete exclusion of the
aneurysmal sac, with shrinkage of 9 mm. We also observed a
7-mm distal migration of the body graft, in absence of neck
dilatation, in one of the patients who received an adjunctive
intraoperative proximal cuff for a type I endoleak. This patient
presents with a stable aneurysmal sac, with no evidence of new
endoleak, and is being observed.
We observed complete resolution within 1 year of five
predischarge type II endoleaks (4.6%) and eight cases of
new-onset type II endoleaks (7.4%). The onset time was 6
months in 4 patients, 1 year in 3 patients, and 2 years in 1
patient. The sources of new onset type II endoleaks were
lumbar arteries in seven patients and the inferior mesenteric
artery in one patient. The overall incidence of type II endoleak
at follow-up was 14.0% (15 patients); in one of these patients,
we observed sac enlargement. Furthermore, there has been no
graft limb thrombosis or limb dislocation.
Shrinkage at 1, 2, 3, and 4 years was observed in 20.9%
(95% CI, 12.9 to 30.4), 30.5% (95% CI, 19.2 to 43.9),
Fig 1. Mid-term survival (Kaplan-Meier). No death was aneu-
rysm- or device-related.38.9% (95% CI, 23.1 to 56.5), and 36.8% (95% CI, 16.3-61.6) of patients (Fig 2). Mean AAA sac size at 1, 2, 3, and
4 years was 47.8  9.2, 46.9  8.9, 43.7  6.5, and 43.8
 7.1 mm. It was significantly reduced from basal value
throughout the 4 years (P .0001).
Preoperative anatomic characteristics (55-mm aneu-
rysm) did not influence the reduction of size with time
(time effect, P .0001; size, P .001; time  aneurysm
size interaction, P  .8). On the contrary, the presence of
type II endoleak influenced the trend of aneurysm size
throughout the 4 years, with aneurysms without endoleak
decreasing more than aneurysms with type II endoleak
(time effect, P .0001; endoleak, P .2; time  endoleak
interaction, P  .0001) (Fig 3).
DISCUSSION
The Excluder endograft received the Conformité Eu-
ropéene (CE) Mark in 1997 and was approved by the
United States Food and Drug Administration in 2002. So
far, it has demonstrated encouraging short- and mid-term
results.1-4,13-15 Several studies, however, demonstrated a
low rate of shrinkage of the sac compared with other
commercially available devices.2-4 Shrinkage rates were 14%
to 35% at 1 year and 19% to 44% at 2 years.2,3,6,14 Further-
more, the presence of an endoleak in patients treated with
the Excluder graft was associated with a greater increase in
sac size than with other devices.4
This behavior might intuitively suggest a detrimental
impact on the clinical success; however, it should be kept in
mind that even the correlation between sac behavior, aneu-
rysmal rupture, and death is not totally clear. It is widely
accepted that ongoing growth of the sac is not a good sign
and may actually herald rupture. On the other hand, a
significant shrinkage of the sac is not necessarily good for
the outcome because this produces two unwanted effects:
1. Anatomic remodelling may be so extensive that the
endograft may no longer be suited to effectively fit the
sac and exclude the aneurysm.
2. It is a widely held view and common observation during
Fig 2. Sac behavior during follow-up.aortic redo operations that the aortic wall of a well-
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thin and atrophic and may no longer be able to with-
stand systemic arterial pressure, despite the reduced size
of the aneurysm.
The combination of these two effects explains why
delayed endoleaks may be symptomatic and produce cata-
strophic effects if not treated emergently.
A stable sac may actually be preferable to both ex-
tremes, and it is by no means proven that a type II endoleak
in the presence of a stable sac is prognostically unfavorable.
Furthermore, aneurysm rupture has been reported in en-
larged, unchanged, or shrunken sacs.16-19
The authors of the EUROSTAR registry have recently
reviewed the data for a 6-year period during which 676
patients received a Gore Excluder graft.15 They compared
patients with AAAs smaller or larger than 5.5 cm:
● Patients with larger AAAs were significantly older and at
higher operative risk, and the anatomic features of the
AAAs were less favorable.
● Device-related endoleaks and additional operative events
were more frequent in patients with large aneurysms.
● The 30-day mortality was similar in the two groups;
however, the overall death rate and aneurysm-related
death were both significantly higher in patients with
large aneurysms.
● Aneurysm growth after treatment was modestly low in
both study groups; there was no correlation between
growth of the sac and aneurysm-related death.
When these results are evaluated, it should be remem-
bered that the data come from 65 different centers with a
mean follow up of 13 months, and 40% of the patients were
lost to follow-up.
It is noteworthy that recently, the first 4-year analysis of
sac behavior with the Excluder endograft reported a 37%
rate of sac enlargement in the absence of endoleak.6 It
Fig 3. Mean abdominal aortic aneurysm sac diameters in patients
with or without the presence of type II endoleak during follow-up.seemed that the most likely cause of sac enlargement wasFig 4. A, Gore Excluder device converted to open surgery (3
years after endovascular aneurysm repair performed at a different
center) for aneurysm (from 7 to 9 cm), possibly owing to trans-
graft passage of fluid from the aortic lumen to the sac. B, The
perigraft gelatinous material is absent in the neck areas (*) and in
the overlapping zone of the graft (arrow), suggesting a role of
expanded polytetrafluoroethylene porosity in its formation.
mplan
ch gr
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sac. The same behavior has been previously reported after
AAA repair with expanded polytetrafluoroethylene
(ePTFE) grafts.20,21 The major concern is the risk of late
rupture of enlarged sacs treated with the Excluder en-
dograft; but to date, no events of this kind were noticed.
The only case of ruptured seroma was reported after open
repair of an AAA with an ePTFE graft.22
Interestingly, we performed one open conversion in a
patient referred to our center for sac enlargement (from 7
cm to 9 cm after 3 years of follow-up) after EVAR per-
formed at another center with the Excluder device (Fig 4).
We observed a retroperitoneal seroma in three of 543
patients treated with bifurcated ePTFE grafts for abdomi-
nal occlusive disease (Fig 5). Of interest is that the gelati-
nous material around the graft in our case of open conver-
sion was absent in the overlap zone between the main body
and the contralateral leg (Fig 4). The same phenomenon
can be noticed at the silicone preconfigured anastomosis in
Fig 2B of the Cuff et al21 report about sac seroma after open
repair with an ePTFE bifurcated graft. This observation
may support the role of ePTFE porosity in the formation of
sac seromas.
Since October 2004, the manufacturer of the Ex-
cluder endograft has introduced in Europe a new device
engineered with a lower permeability of the material.
This may reduce the potential for serous fluid passage
through the graft wall. Future studies comparing the low
porosity endograft with the older device will be impor-
tant to determine if permeability of ePTFE is the key to
explain the high rate of unchanged aneurysmal sac size.
Expanded PTFE shows a low thrombogenicity.23,24 In
Fig 5. Retroperitoneal seroma in a patient 2 years after i
Goretex (W.L. Gore and Assoc, Flagstaff, Arizona) stretthis and other previous studies,3,25 no limb occlusionwas reported, and we believe that this characteristic can
possibly contribute to the lower rate of complete sac
thrombosis reported with the Excluder graft.
In this experience with a selected cohort of patients
with favorable aortic morphology and excluding patients
with grade III and IV aneurysms, the Excluder endograft
provided a high rate of clinical success without aneurysmal-
related deaths or late conversions. The rate of shrinkage
during the 4-year follow-up was low, but no case of sac
enlargement because of endotension was recorded and no
adverse events were noticed in unchanged aneurysmal sacs.
The only two cases of sac enlargement were due, respec-
tively, to type IA and II endoleaks. Not surprisingly the
only factor that negatively affected shrinkage in our analysis
was the presence of type II endoleak during follow-up. A
direct correlation between55-mm aneurysms and shrink-
age was not found in our analysis. On the other hand, Cho
et al6 demonstrated that smaller aneurysms (5 cm) exhib-
ited a higher incidence of sac shrinkage than did larger
aneurysms; however, we have no information regarding the
initial aneurysm diameter (mean  SD) of the series.
Moreover, age, gender, medications, smoking status,
hypertension, cholesterol levels, aneurysmal morphology
and extension, among others, have been reported to influ-
ence the behavior of untreated abdominal aortic aneu-
rysms.26-29 These factors may play a role also in shrinkage
after endovascular repair thus justifying different results in
different studies.
Changes do happen, even within sacs that have stable
dimensions. We have noticed that even if the total number
of type II endoleaks is relatively stable with time, this is due
to the balance between leaks that spontaneously resolve and
tation of a bifurcated expanded polytetrafluoroethylene
aft for occlusive disease (no aneurismal sac).ones of new onset.Moreover, as previously observed, in our
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initially positioned in the central area of the aneurysm to
move anteriorly towards the anterior wall of the sac. The
necks, the overlaps, and the flexibility of the grafts should
be planned to accommodate for this common effect with-
out causing problems.
The current study refers to a series of selected patients
with a mean follow-up of 29 months; however, the number
of patients followed for4 years was identical (19 patients)
to that of Cho et al,6 and for 3 years it was greater (36 vs 29
patients). Our shorter mean follow-up may be explained by
the presence of more patients followed for 1 year.
Limitations of our study include the relatively small
number of patients and the length of follow-up. Addition-
ally, our reported series deals with aneurysms 55 mm in
63% of patients. The initial size of the aneurysm may be a
factor that influences results and clinical success rate.
CONCLUSION
This analysis of sac behavior after EVAR with the
Excluder endograft showed that there is a low but sig-
nificant rate of sac shrinkage. Unchanged aneurysmal
sacs tend to be stable and not prone to enlargement. This
behavior has not been associated with a detrimental
effect in the clinical outcome. Longer follow-up will
reveal the true impact of sac behavior on AAA rupture
prevention.
We thank Giliola Calori, MD, from the Statistic unit of
Scientific Institute San Raffaele Milan, for her assistance
with statistical analysis.
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